Market Research Logo

The Worldwide Market for Targeted Cancer Therapeutics

The Worldwide Market for Targeted Cancer Therapeutics

Kalorama Information has watched the cancer treatment market evolve over the past two decades and evaluated the impact new technologies are making on the market. Worldwide Market for Targeted Cancer Therapeutics focuses on the expanding area of targeted therapies and includes current products available and discusses some of the most exciting developments in progress. This report covers targeted cancer therapies that do at least one of the following:

  • Block or turn off chemical signals that tell the cancer cell to grow and divide
  • Change proteins within the cancer cells so the cells die
  • Stop making new blood vessels to feed the cancer cells
  • Trigger the immune system to kill the cancer cells
  • Carry toxins to the cancer cells to kill them, but not normal cells
This report on the targeted cancer therapeutics market specifically focuses on five leading segments of targeted therapies – monoclonal antibodies, tyrosine kinase inhibitors, angiogenesis inhibitors, CDK inhibitors, and proteasome inhibitors – providing information on a global level, including:
  • Global Targeted Cancer Therapeutic Market Size and Forecast, 2010-2025 ($millions) (monoclonal antibodies, tyrosine kinase inhibitors, angiogenesis inhibitors, proteasome inhibitors, CDK inhibitors, others)
  • Cancer Monoclonal Antibody Market, 2018-2025 ($ millions)
  • Top 10 Cancer Indicated Monoclonal Antibodies, 2017 and 2018 Sales (millions $)
  • Monoclonal Antibodies in Cancer Therapy (Trade Name, Biological Name, Target, Indication[s])
  • Tyrosine Kinase Inhibitor Market, 2018-2025 ($ millions)
  • Top 10 Cancer Indicated Tyrosine Kinase Inhibitors, 2017 and 2018 Sales (millions $)
  • Tyrosine Kinase Inhibitors in Cancer Therapy (Trade Name, Biological Name, Target, Indication[s])
  • Angiogenesis Inhibitor Market, 2018-2025 ($ millions)
  • Angiogenesis Inhibitors in Cancer Therapy (Trade Name, Biological Name, Indication[s])
  • CDK Inhibitor Market, 2018-2025: ($ millions)
  • CDK Inhibitors in Cancer Therapy (Trade Name, Biological Name, Target, Indication[s])
  • Proteasome Inhibitor Market, 2018-2025: ($ millions)
  • Proteasome Inhibitors in Cancer Therapy (Trade Name, Biological Name, Target, Indication[s])
  • Other Targeted Therapies Market, 2018-2025: ($ millions)
  • Other Targeted Cancer Therapies (Classification, Trade Name, Biological Name, Target, Indication[s])
The report also provides specific information by type and by target on a global level for the monoclonal antibodies (mAbs) and tyrosine kinase inhibitors (TKI) segments, including:
  • Cancer Monoclonal Antibody Market by Type
  • Development of the mAb Cancer Treatment Market, 2010-2025 (Breast Cancer, Colorectal Cancer, Lymphoma, Leukemia, Myeloma, Melanoma, Lung, Renal, Others)
  • Monoclonal Antibody Market by Cancer Type, 2018 and 2025 ($ millions) (Breast, Lymphoma, Lung, Colorectal, Melanoma, Multiple Myeloma, Kidney, Leukemia, Ovarian, Urothelial, Head/Neck, GIST, Brain, Sarcoma, Liver, Other Solid Tumors, Other undisclosed/Unknown)
  • Monoclonal Antibody Market, Distribution by Cancer Type, 2018 (%) (Breast, Lymphoma, Lung, Colorectal, Melanoma, Multiple Myeloma, Kidney, Leukemia, Ovarian, Urothelial, Head/Neck, GIST, Brain, Sarcoma, Liver, Other Solid Tumors, Other undisclosed/Unknown)
  • Monoclonal Antibody Market Distribution by Indication, 2025 (%) (Breast, Lymphoma, Lung, Colorectal, Melanoma, Multiple Myeloma, Kidney, Leukemia, Ovarian, Urothelial, Head/Neck, GIST, Brain, Sarcoma, Liver, Other Solid Tumors, Other undisclosed/Unknown)
  • Cancer Tyrosine Kinase Inhibitor Market by Type
  • Development of the TKI Cancer Treatment Market, 2010-2025 (Leukemia, Lung, Lymphoma, Kidney, Melanoma, GIST, Liver, Pancreatic, Breast, Thyroid, Colorectal, Other)
  • TKI Market by Cancer Indication, 2018 and 2025 ($ millions) (Leukemia, Lung, Lymphoma, Kidney, Melanoma, GIST, Liver, Pancreatic, Breast, Thyroid, Colorectal, Other)
  • TKI Market Distribution by Cancer Indication, 2018 (%) (Leukemia, Lung, Lymphoma, Kidney, Melanoma, GIST, Liver, Pancreatic, Breast, Thyroid, Colorectal, Other)
  • TKI Market Distribution by Cancer Indication, 2025 (%) (Leukemia, Lung, Lymphoma, Kidney, Melanoma, GIST, Liver, Pancreatic, Breast, Thyroid, Colorectal, Other)
  • Cancer Monoclonal Antibody Market by Target
  • Cancer Monoclonal Antibody Market by Target, 2018 and Forecast 2025 ($ millions) (PD-1, HER2, VEGF, CD20, EGFR, CD38, RANKL, CTLA-4, PD-L1, CD30, PDGF)
  • Cancer Monoclonal Antibody Market Distribution by Target, 2018 (%) (PD-1, HER2, VEGF, CD20, EGFR, CD38, RANKL, CTLA-4, PD-L1, CD30, PDGF)
  • Cancer Monoclonal Antibody Market Distribution by Target, 2025 (%) (PD-1, HER2, VEGF, CD20, EGFR, CD38, RANKL, CTLA-4, PD-L1, CD30, PDGF)
  • Cancer Tyrosine Kinase Inhibitor Market by Target
  • Cancer TKI Market by Target, 2018 and Forecast 2025 ($ millions) (Single Target: ALK, ABL, BTK, EGFR, VEGF, HER2, BRAF, Others; Multi-target)
  • TKI Market Distribution by Target, 2018 (%) (ALK, ABL, BTK, EGFR, VEGF, HER2, BRAF, Others; Multi-target)
  • TKI Market Distribution by Target, 2025 (%) (ALK, ABL, BTK, EGFR, VEGF, HER2, BRAF, Others; Multi-target)
The United States cancer pharmaceutical industry is the largest in terms of revenues generated. Western European markets are major drivers for innovative cancer treatment markets with growing sales in emerging Eastern European markets. Asia Pacific sales are driven by established economies such as Japan and Australia and emerging markets such as China. Cancer treatment markets have been slower to develop in Latin American markets, with targeted therapies often secondary to traditional chemotherapy or hormone therapy. Worldwide Market for Targeted Cancer Therapeutics provides regional market overviews, encompassing United States and Canada; Europe, Middle East and Africa (EMEA); Asia Pacific; and Latin America:
  • Targeted Cancer Therapeutics Market Summary by Geographical Region, 2018-2025 ($ millions) (United States and Canada; Europe, Middle East, Africa (EMEA); Asia Pacific; Latin America; Global Market)
  • United States and Canada
  • Targeted Cancer Therapeutics Market Summary for U.S. and Canada, 2018-2025 ($ millions) (Monoclonal antibodies, Tyrosine kinase inhibitors, Angiogenesis Inhibitors, Proteasome inhibitors, CDK inhibitors, Other targeted therapies, Total)
  • Targeted Cancer Therapeutics for U.S. and Canada, Distribution by Therapy Type (monoclonal antibodies, tyrosine kinase inhibitors, angiogenesis inhibitors, proteasome inhibitors, CDK inhibitors, other targeted therapies), 2018 %
  • EMEA
  • Targeted Cancer Therapeutics Market Summary for EMEA, 2018-2025 ($ millions) (Monoclonal antibodies, Tyrosine kinase inhibitors, Angiogenesis Inhibitors, Proteasome inhibitors, CDK inhibitors, Other targeted therapies, Total)
  • Targeted Cancer Therapeutics for EMEA, Distribution by Therapy Type (monoclonal antibodies, tyrosine kinase inhibitors, angiogenesis inhibitors, proteasome inhibitors, CDK inhibitors, other targeted therapies), 2018 %
  • Asia Pacific
  • Targeted Cancer Therapeutics Market Summary for Asia Pacific, 2018-2025 ($ millions) (Monoclonal antibodies, Tyrosine kinase inhibitors, Angiogenesis Inhibitors, Proteasome inhibitors, CDK inhibitors, Other targeted therapies, Total)
  • Targeted Cancer Therapeutics for Asia Pacific, Distribution by Therapy Type (monoclonal antibodies, tyrosine kinase inhibitors, angiogenesis inhibitors, proteasome inhibitors, CDK inhibitors, other targeted therapies), 2018 %
  • Latin America
  • Targeted Cancer Therapeutics Market Summary for Latin America, 2018-2025 ($ millions) (Monoclonal antibodies, Tyrosine kinase inhibitors, Angiogenesis Inhibitors, Proteasome inhibitors, CDK inhibitors, Other targeted therapies, Total)
  • Targeted Cancer Therapeutics for Latin America, Distribution by Therapy Type (monoclonal antibodies, tyrosine kinase inhibitors, angiogenesis inhibitors, proteasome inhibitors, CDK inhibitors, other targeted therapies), 2018 %
The report includes competitive summaries of the leading market providers. In addition, the report provides competitor market share in major market segments, including:
  • Cancer Monoclonal Antibody Competitor Market Share - Top Seven, 2018 ($ millions)
  • Cancer TKI Competitor Market Share, 2018 ($ millions)
  • Cancer CDK Inhibitors Competitor Market Share, 2018 ($ millions)
  • Cancer Proteasome Inhibitor Competitor Market Share, 2018 ($ millions)
Worldwide Market for Targeted Cancer Therapeutics concludes with profiles of the leading competitors in the targeted cancer therapeutic market, including:
  • AbbVie, Inc.
  • Adaptimmune Therapeutics plc.
  • Advantagene, Inc.
  • Agenus, Inc.
  • Amgen
  • Anchiano Therapeutics
  • Apceth Biopharma GmbH & Co. KG
  • Apollomics, Inc.
  • Aptevo Therapeutics
  • AstraZeneca PLC
  • Aurobindo Pharma Ltd.
  • Bayer AG
  • Bellicum Pharmaceuticals, Inc.
  • Biocon Ltd
  • BioInvent International AB
  • bluebird bio, Inc.
  • Boehringer Ingelheim
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Celldex Therapeutics
  • Celltrion, Inc.
  • Celsion Corporation
  • Clovis Oncology, Inc.
  • Cold Genesys, Inc.
  • Dendreon Pharmaceuticals LLC
  • Eisai Co., Ltd.
  • Eli Lilly & Company
  • EMD Serono, Inc. (Merck KgaA)
  • Exelixis, Inc.
  • Gamida Cell Ltd.
  • Genprex, Inc.
  • Gilead Sciences, Inc.
  • Immunomedics, Inc.
  • Incyte Corporation
  • Innate Pharma S.A.
  • Inovio Pharmaceuticals, Inc.
  • Johnson & Johnson
  • MacroGenics, Inc.
  • Merck & Co., Inc.
  • Merrimack Pharmaceuticals, Inc.
  • Nascent Biotech
  • Northwest Biotherapeutics, Inc.
  • Novartis AG
  • Oncolytics Biotech, Inc.
  • OncoMed Pharmaceuticals, Inc.
  • OncoSec Medical, Inc.
  • Oncternal Therapeutics
  • Otsuka Holdings Co., Ltd.
  • Pfizer, Inc.
  • Puma Biotechnology, Inc.
  • Regeneron Pharmaceuticals
  • Roche (F. Hoffman-La Roche, Ltd.)
  • Sanofi
  • Seattle Genetics, Inc.
  • Sesen Bio
  • Sorrento Therapeutics
  • Takeda Oncology - Millennium Pharmaceuticals
  • TESARO, Inc.
  • TG Therapeutics, Inc.
  • Tocagen, Inc.
  • Vascular Biogenics Ltd.
  • ZIOPHARM Oncology, Inc.


  • Executive Summary
    • Overview
    • Scope and Methodology
    • Market Overview and Analysis
      • Table Global Targeted Cancer Therapeutic Market Size and Forecast, 2010-2025 ($millions)
  • Introduction
    • Global Cancer Burden
      • Table Global Cancer Incidence Trends, 2010-2040
      • Table Incidence of Cancer by Type, 2018
      • Table Distribution of Cancer Incidence by Type, 2018
    • Introduction to Cancer
      • Biochemistry of Cancer Cells
    • Causes of Cancer Growth May Shed Light on Treatment
      • Environmental Factors, DNA, RNA
        • Table Virus Association with Human Cancer
      • Cellular Oncogenes
      • Tumor Suppressor Genes
    • Cancer Treatment Approaches
      • Table Characteristics of Cancer Treatment Approaches (chemotherapy, hormone therapy, targeted therapy)
    • What Is Targeted Cancer Therapy?
    • Trends in Research and Development of Targeted Cancer Therapeutics
    • Cancer Treatment Market Outlook: Targeted vs. Broad Treatments
      • Table Targeted vs. Broad Treatments for Cancer, 2010-2025
    • Monoclonal Antibodies: The Leading Area of Cancer Targeted Therapy
  • Targeted Cancer Therapies: Monoclonal Antibodies
    • Monoclonal Antibody Overview
    • Market Outlook
      • Table Cancer Monoclonal Antibody Market, 2018-2025 ($ millions)
    • Principal Products
      • Table Top 10 Cancer Indicated Monoclonal Antibodies, 2017 and 2018 Sales (millions $)
      • Table Top 10 Cancer Indicated Monoclonal Antibodies, 2017 and 2018 Sales (millions $)
      • Avastin (bevacizumab)
      • Darzalex (daratumumab)
      • Erbitux (cetuximab)
      • Herceptin (trastuzumab)
      • Kadcyla (ado-trastuzumab emtansine)
      • Keytruda (pembrolizumab)
      • Opdivo (nivolumab)
      • Perjeta (pertuzumab)
      • Rituxan (rituximab)
      • Yervoy (ipilimumab)
      • Xgeva (denosumab)
        • Table Monoclonal Antibodies in Cancer Therapy
    • Market Breakdown of Monoclonal Antibodies
      • Cancer Monoclonal Antibody Market by Target
        • Table Cancer Monoclonal Antibody Market by Target, 2018 and Forecast 2025 ($ millions)
        • Table Cancer Monoclonal Antibody Market by Target, 2018 and 2025 ($ millions)
        • Table Cancer Monoclonal Antibody Market Distribution by Target, 2018 (%)
        • Table Cancer Monoclonal Antibody Market Distribution by Target, 2025 (%)
      • Cancer Monoclonal Antibody Market by Type
        • Table Development of the mAb Cancer Treatment Market, 2010-2025
        • Table Cancer Treatment mAb Market by Type, 2018-2025 ($ millions)
        • Table Monoclonal Antibody Market by Cancer Type, 2018 and 2025 ($ millions)
        • Table Monoclonal Antibody Market, Distribution by Cancer Type, 2018 (%)
        • Table Monoclonal Antibody Market Distribution by Indication, 2025 (%)
    • Regional Market Summary
      • Table Cancer Monoclonal Antibody Market Summary by Geographic Region, 2018 and 2025 ($ millions)
    • Competitor Summary
      • Genentech/Roche
      • Bristol-Myers Squibb
      • Merck & Co.
      • Amgen
      • Janssen Biotech/J&J
      • Eli Lilly & Co.
      • EMD Serono
        • Table Cancer Monoclonal Antibody Competitor Market Share - Top Seven, 2018 ($ millions)
  • Targeted Cancer Therapies: Tyrosine Kinase Inhibitors
    • Tyrosine Kinase Inhibitor Overview
    • Market Outlook
      • Table Tyrosine Kinase Inhibitor Market, 2018-2025 ($ millions)
    • Principal Products
      • Table Top 10 Cancer Indicated Tyrosine Kinase Inhibitors, 2017 and 2018 Sale (millions $)
      • Table Top 10 Cancer Indicated Tyrosine Kinase Inhibitors, 2017 and 2018 Sales (millions $)
      • Imbruvica (ibrutinib)
      • Sprycel (dasatinib)
      • Tasigna (nilotinib)
      • Tagrisso (osimertinib)
      • Gleevec (imatinib)
      • Mekinist+Tafinlar (trametinib + dabrafenib)
      • Sutent (sunitinib)
      • Jakafi/Jakavi (ruxolitinib)
      • Nexavar (sorafenib)
      • Votrient (pazopanib)
        • Table Tyrosine Kinase Inhibitors in Cancer Therapy
    • Market Breakdown of Tyrosine Kinase Inhibitors
      • Cancer Tyrosine Kinase Inhibitor Market by Target
        • Table Cancer TKI Market by Target, 2018 and Forecast 2025 ($ millions)
        • Table Cancer TKI Market by Target, 2018 and 2025 ($ millions)
        • Table TKI Market Distribution by Target, 2018 (%)
        • Table TKI Market Distribution by Target, 2025 (%)
      • Cancer Tyrosine Kinase Inhibitor Market by Type
        • Table Development of the TKI Cancer Treatment Market, 2010-2025
        • Table Cancer Treatment TKI Market by Type, 2018-2025 ($ millions)
        • Table TKI Market by Cancer Indication, 2018 and 2025 ($ millions)
        • Table TKI Market Distribution by Cancer Indication, 2018 (%)
        • Table TKI Market Distribution by Cancer Indication, 2025 (%)
    • Regional Market Summary
      • Table Cancer Tyrosine Kinase Inhibitor Market Summary by Geographic Region, 2018 and 2025 ($ millions)
    • Competitor Summary
      • Novartis
      • AbbVie
      • Johnson & Johnson
      • AstraZeneca
      • Pfizer
      • Bristol-Myers Squibb
      • Roche/Genentech
        • Table Cancer TKI Competitor Market Share, 2018 ($ millions)
  • Targeted Cancer Therapies: Angiogenesis Inhibitors
    • Angiogenesis Inhibitor Overview
    • Market Outlook
      • Table Angiogenesis Inhibitor Market, 2018-2025 ($ millions)
    • Principal Products
      • Pomalyst/Imnovid (pomalidomide)
      • Revlimid (lenalidomide)
      • Thalomid (thalidomide)
      • Zaltrap (ziv-aflibercept)
        • Table Angiogenesis Inhibitors in Cancer Therapy
    • Regional Market Summary
      • Table Cancer Angiogenesis Inhibitor Market Summary by Geographic Region, Estimated 2018 and 2025 ($ millions)
    • Competitor Summary
  • Targeted Cancer Therapies: CDK Inhibitors
    • CDK Inhibitor Overview
    • Market Outlook
      • Table CDK Inhibitor Market, 2018-2025: ($ millions)
    • Principal Products
      • Ibrance (palbociclib)
      • Kisqali (ribociclib)
        • Table CDK Inhibitors in Cancer Therapy
    • Regional Market Summary
      • Table Cancer CDK Inhibitor Market Summary by Geographic Region, Estimated 2018 and 2025 ($ millions)
    • Competitor Summary
      • Pfizer
      • Novartis
        • Table Cancer CDK Inhibitors Competitor Market Share, 2018 ($ millions)
  • Targeted Cancer Therapies: Proteasome Inhibitors
    • Proteasome Inhibitor Overview
    • Market Outlook
      • Table Proteasome Inhibitor Market, 2018-2025: ($ millions)
    • Principal Products
      • Kyprolis (carfilzomib)
      • Ninlaro (ixazomib)
      • Velcade (bortezomib)
        • Table Proteasome Inhibitors in Cancer Therapy
    • Regional Market Summary
      • Table Cancer Proteasome Inhibitor Market Summary by Geographic Region, Estimated 2018 and 2025 ($ millions)
    • Competitor Summary
      • Takeda
      • Johnson & Johnson
      • Amgen
        • Table Cancer Proteasome Inhibitor Competitor Market Share, 2018 ($ millions)
  • Targeted Cancer Therapies: Other Targeted Therapies
    • Other Targeted Therapies Overview
    • Market Outlook
      • Table Other Targeted Therapies Market, 2018-2025: ($ millions)
    • Principal Products
      • mTOR Inhibitor - Afinitor (everolimus)
      • mmTOR Inhibitor - Torisel (temsirolimus)
      • PI3K Inhibitor - Zydelig
      • PARP Inhibitor - Lynparza
      • PARP Inhibitor - Zejula
      • Apoptosis Inducer - Venclexta
        • Table Other Targeted Cancer Therapies
    • Regional Market Summary
      • Table Other Targeted Therapies Market Summary by Geographic Region, Estimated 2018 and 2025 ($ millions)
  • Market Summary
    • Market Influences
      • Global Demographics
        • Table Global Population, 1980 through 2050 (population in millions)
        • Table Global Population Trends, Total Population vs. Age 65+ Population, 2000-2050
      • Cancer: A Growing Economic Burden
      • Cost Containment
        • Table The Cost of Monoclonal Antibodies
      • Reimbursement Landscape: A Deciding Factor for Success
      • The Biosimilar Movement
    • Regional Market Overview
      • Table Targeted Cancer Therapeutics Market Summary by Geographical Region, 2018-2025 ($ millions)
    • United States and Canada
      • Table Targeted Cancer Therapeutics Market Summary for U.S. and Canada, 2018-2025 ($ millions)
      • Table Targeted Cancer Therapeutics for U.S. and Canada, Distribution by Therapy Type (monoclonal antibodies, tyrosine kinase inhibitors, angiogenesis inhibitors, proteasome inhibitors, CDK inhibitors, other targeted therapies), 2018 %
    • EMEA
      • Table Targeted Cancer Therapeutics Market Summary for EMEA, 2018-2025 ($ millions)
      • Table Targeted Cancer Therapeutics for EMEA, Distribution by Therapy Type (monoclonal antibodies, tyrosine kinase inhibitors, angiogenesis inhibitors, proteasome inhibitors, CDK inhibitors, other targeted therapies), 2018 %
    • Asia Pacific
      • Table Targeted Cancer Therapeutics Market Summary for Asia Pacific, 2018-2025 ($ millions)
      • Table Targeted Cancer Therapeutics for Asia Pacific, Distribution by Therapy Type (monoclonal antibodies, tyrosine kinase inhibitors, angiogenesis inhibitors, proteasome inhibitors, CDK inhibitors, other targeted therapies), 2018 %
    • Latin America
      • Table Targeted Cancer Therapeutics Market Summary for Latin America, 2018-2025 ($ millions)
      • Table Targeted Cancer Therapeutics for Latin America, Distribution by Therapy Type (monoclonal antibodies, tyrosine kinase inhibitors, angiogenesis inhibitors, proteasome inhibitors, CDK inhibitors, other targeted therapies), 2018 %
  • Market Participants
    • Top 15 Overview
      • Table Global Market Participants for Targeted Cancer Therapeutics, Top 15 Companies, 2018 ($ in millions)
      • Table Global Market Share for Targeted Cancer Therapeutics, 2018 %
      • Table Growth in Targeted Cancer Therapeutics by Company 2010 vs. 2018 ($ in millions)
      • Table Growth Trend by Company, 2010-2018 CAGR: Targeted Cancer Therapeutics
    • AbbVie, Inc.
      • Table AbbVie Corporate Summary
      • Company Summary
    • Adaptimmune Therapeutics plc.
      • Table Adaptimmune Corporate Summary
      • Company Summary
    • Advantagene, Inc.
      • Table Advantagene Corporate Summary
      • Company Summary
    • Agenus, Inc.
      • Table Agenus Corporate Summary
      • Company Summary
    • Amgen
      • Table Amgen Corporate Summary
      • Company Summary
    • Anchiano Therapeutics
      • Table Anchiano Therapeutics Corporate Summary
      • Company Summary
    • Apceth Biopharma GmbH & Co. KG
      • Table Apceth Corporate Summary
      • Company Summary
    • Apollomics, Inc.
      • Table Apollomics Corporate Summary
      • Company Summary
    • Aptevo Therapeutics
      • Table Aptevo Corporate Summary
      • Company Summary
    • AstraZeneca PLC
      • Table AstraZeneca Corporate Summary
      • Company Summary
    • Aurobindo Pharma Ltd.
      • Table Aurobindo Corporate Summary
      • Company Summary
    • Bayer AG
      • Table Bayer Corporate Summary
      • Company Summary
    • Bellicum Pharmaceuticals, Inc.
      • Table Bellicum Pharmaceuticals Corporate Summary
      • Company Summary
    • Biocon Ltd
      • Table Biocon Corporate Summary
      • Company Summary
    • BioInvent International AB
      • Table BioInvent Corporate Summary
      • Company Summary
    • bluebird bio, Inc.
      • Table bluebird bio Corporate Summary
      • Company Summary
    • Boehringer Ingelheim
      • Table Boehringer Ingelheim Corporate Summary
      • Company Summary
    • Bristol-Myers Squibb Company
      • Table Bristol-Myers Squibb Corporate Summary
      • Company Summary
    • Celgene Corporation
      • Table Celgene Corporate Summary
      • Company Summary
    • Celldex Therapeutics
      • Table Celldex Therapeutics Corporate Summary
      • Company Summary
    • Celltrion, Inc.
      • Table Celltrion Corporate Summary
      • Company Summary
    • Celsion Corporation
      • Table Celsion Corporate Summary
      • Company Summary
    • Clovis Oncology, Inc.
      • Table Clovis Oncology Corporate Summary
      • Company Summary
    • Cold Genesys, Inc.
      • Table Cold Genesys Corporate Summary
      • Company Summary
    • Dendreon Pharmaceuticals LLC
      • Table Dendreon Corporate Summary
      • Company Summary
    • Eisai Co., Ltd.
      • Table Eisai Corporate Summary
      • Company Summary
    • Eli Lilly & Company
      • Table Eli Lilly Corporate Summary
      • Company Summary
    • EMD Serono, Inc. (Merck KgaA)
      • Table EMD Serono Corporate Summary
      • Company Summary
    • Exelixis, Inc.
      • Table Exelixis Corporate Summary
      • Company Summary
    • Gamida Cell Ltd.
      • Table Gamida Cell Corporate Summary
      • Company Summary
    • Genprex, Inc.
      • Table Genprex Corporate Summary
      • Company Summary
    • Gilead Sciences, Inc.
      • Table Gilead Sciences Corporate Summary
      • Company Summary
    • Immunomedics, Inc.
      • Table Immunomedics Corporate Summary
      • Company Summary
    • Incyte Corporation
      • Table Incyte Corporate Summary
      • Company Summary
    • Innate Pharma S.A.
      • Table Innate Pharma Corporate Summary
      • Company Summary
    • Inovio Pharmaceuticals, Inc.
      • Table Inovio Pharmaceuticals Corporate Summary
      • Company Summary
    • Johnson & Johnson
      • Table Johnson & Johnson Corporate Summary
      • Company Summary
    • MacroGenics, Inc.
      • Table MacroGenics Corporate Summary
    • Merck & Co., Inc.
      • Table Merck & Co. Corporate Summary
      • Company Summary
    • Merrimack Pharmaceuticals, Inc.
      • Table Merrimack Corporate Summary
      • Company Summary
    • Nascent Biotech
      • Table Nascent Biotech Corporate Summary
      • Company Summary
    • Northwest Biotherapeutics, Inc.
      • Table Northwest Biotherapeutics Corporate Summary
      • Company Summary
    • Novartis AG
      • Table Novartis Corporate Summary
      • Company Summary
    • Oncolytics Biotech, Inc.
      • Table Oncolytics Biotech Corporate Summary
      • Company Summary
    • OncoMed Pharmaceuticals, Inc.
      • Table OncoMed Pharmaceuticals Corporate Summary
      • Company Summary
    • OncoSec Medical, Inc.
      • Table OncoSec Medical Corporate Summary
      • Company Summary
    • Oncternal Therapeutics
      • Table Oncternal Therapeutics Corporate Summary
      • Company Summary
    • Otsuka Holdings Co., Ltd.
      • Table Otsuka Corporate Summary
      • Company Summary
    • Pfizer, Inc.
      • Table Pfizer Corporate Summary
      • Company Summary
    • Puma Biotechnology, Inc.
      • Table Puma Biotechnology Corporate Summary
      • Company Summary
    • Regeneron Pharmaceuticals
      • Table Regeneron Corporate Summary
      • Company Summary
    • Roche (F. Hoffman-La Roche, Ltd.)
      • Table Roche Corporate Summary
      • Company Summary
    • Sanofi
      • Table Sanofi Corporate Summary
      • Company Summary
    • Seattle Genetics, Inc.
      • Table Seattle Genetics Corporate Summary
      • Company Summary
    • Sesen Bio
      • Table Sesen Bio Corporate Summary
      • Company Summary
    • Sorrento Therapeutics
      • Table Sorrento Therapeutics Corporate Summary
      • Company Summary
    • Takeda Oncology - Millennium Pharmaceuticals
      • Table Takeda Oncology Corporate Summary
      • Company Summary
    • TESARO, Inc.
      • Table TESARO Corporate Summary
      • Company Summary
    • TG Therapeutics, Inc.
      • Table TG Therapeutics Corporate Summary
      • Company Summary
    • Tocagen, Inc.
      • Table Tocagen Corporate Summary
      • Company Summary
    • Vascular Biogenics Ltd.
      • Table Vascular Biogenics Corporate Summary
      • Company Summary
    • ZIOPHARM Oncology, Inc.
      • Table ZIOPHARM Oncology Corporate Summary
      • Company Summary

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report